Skip to main content
. 2020 Apr 27;25(9):2031. doi: 10.3390/molecules25092031

Figure 1.

Figure 1

Chemical structures for the approved CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib), approved oxindole-based anticancer drug (sunitinib), some reported oxindole-based anticancer hybrids (I–III), and the target hybrids (6a–i, 9a–f, and 11a,b).